232 related articles for article (PubMed ID: 15544491)
21. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis.
Geller BL; Deere J; Tilley L; Iversen PL
J Antimicrob Chemother; 2005 Jun; 55(6):983-8. PubMed ID: 15872045
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
Touznik A; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
[TBL] [Abstract][Full Text] [Related]
23. Understanding Antisense Oligonucleotide Efficiency in Inhibiting Prokaryotic Gene Expression.
Story S; Bhaduri S; Ganguly S; Dakarapu R; Wicks SL; Bhadra J; Kwange S; Arya DP
ACS Infect Dis; 2024 Mar; 10(3):971-987. PubMed ID: 38385613
[TBL] [Abstract][Full Text] [Related]
24. Systemic and ICV Injections of Antisense Oligos into SMA Mice and Evaluation.
Aslesh T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():455-465. PubMed ID: 30171559
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers.
Geller BL; Deere JD; Stein DA; Kroeker AD; Moulton HM; Iversen PL
Antimicrob Agents Chemother; 2003 Oct; 47(10):3233-9. PubMed ID: 14506035
[TBL] [Abstract][Full Text] [Related]
26. Chimeras of Cell-Penetrating Peptides Demonstrate Synergistic Improvement in Antisense Efficacy.
Fadzen CM; Holden RL; Wolfe JM; Choo ZN; Schissel CK; Yao M; Hanson GJ; Pentelute BL
Biochemistry; 2019 Sep; 58(38):3980-3989. PubMed ID: 31450889
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic applications of antisense oligonucleotides in asthma and allergy.
Isidoro-García M; Dávila I
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic antisense and ribozymes.
Rossi JJ
Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
[TBL] [Abstract][Full Text] [Related]
29. Antisense antibiotics: a brief review of novel target discovery and delivery.
Bai H; Xue X; Hou Z; Zhou Y; Meng J; Luo X
Curr Drug Discov Technol; 2010 Jun; 7(2):76-85. PubMed ID: 20836761
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers.
Stein DA; Skilling DE; Iversen PL; Smith AW
Antisense Nucleic Acid Drug Dev; 2001 Oct; 11(5):317-25. PubMed ID: 11763348
[TBL] [Abstract][Full Text] [Related]
31. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
32. Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin.
Pannier AK; Arora V; Iversen PL; Brand RM
Int J Pharm; 2004 May; 275(1-2):217-26. PubMed ID: 15081152
[TBL] [Abstract][Full Text] [Related]
33. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture.
van den Born E; Stein DA; Iversen PL; Snijder EJ
J Gen Virol; 2005 Nov; 86(Pt 11):3081-3090. PubMed ID: 16227231
[TBL] [Abstract][Full Text] [Related]
34. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics.
Zhou T; Kim Y; MacLeod AR
Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of Morpholino Monomers, Chlorophosphoramidate Monomers, and Solid-Phase Synthesis of Short Morpholino Oligomers.
Bhadra J; Pattanayak S; Sinha S
Curr Protoc Nucleic Acid Chem; 2015 Sep; 62():4.65.1-4.65.26. PubMed ID: 26380905
[TBL] [Abstract][Full Text] [Related]
36. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
Phillips MI
Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
[TBL] [Abstract][Full Text] [Related]
37. Systemic delivery of antisense oligomer in animal models and its implications for treating DMD.
Lu QL; Wu B
Methods Mol Biol; 2012; 867():393-405. PubMed ID: 22454075
[TBL] [Abstract][Full Text] [Related]
38. Generation of Protein-Phosphorodiamidate Morpholino Oligomer Conjugates for Efficient Cellular Delivery via Anthrax Protective Antigen.
Palacio-Castañeda V; Brock R; Verdurmen WPR
Methods Mol Biol; 2022; 2434():129-141. PubMed ID: 35213014
[TBL] [Abstract][Full Text] [Related]
39. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
40. Antisense treatments for biothreat agents.
Warfield KL; Panchal RG; Aman MJ; Bavari S
Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
